LT3645553T - Modifikuoto tropizmo rekombinantinės viruso dalelės ir jų panaudojimas genetinės medžiagos tiksliniam įvedimui į žmogaus ląsteles - Google Patents

Modifikuoto tropizmo rekombinantinės viruso dalelės ir jų panaudojimas genetinės medžiagos tiksliniam įvedimui į žmogaus ląsteles

Info

Publication number: LT3645553T
Authority: LT; Lithuania
Prior art keywords: tropism; human cells; genetic material; viral particles; recombinant viral
Prior art date: 2017-06-27

Application number

LTEPPCT/US2018/039878T

Other languages

English (en)

Inventor

Leah SABIN

Christopher Schoenherr

Aris N. Economides

Christos Kyratsous

Andrew J. Murphy

Original Assignee

Regeneron Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-06-27

Filing date

2018-06-27

Publication date

2023-04-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63080488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3645553(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-06-27 Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.

2023-04-25 Publication of LT3645553T publication Critical patent/LT3645553T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14123—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Epidemiology (AREA)
Oncology (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

LTEPPCT/US2018/039878T 2017-06-27 2018-06-27 Modifikuoto tropizmo rekombinantinės viruso dalelės ir jų panaudojimas genetinės medžiagos tiksliniam įvedimui į žmogaus ląsteles LT3645553T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762525708P	2017-06-27	2017-06-27
PCT/US2018/039878 WO2019006046A2 (en)	2017-06-27	2018-06-27	RECOMBINANT VIRAL PARTICLES WITH MODIFIED TROPISM AND USES THEREOF FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS

Publications (1)

Publication Number	Publication Date
LT3645553T true LT3645553T (lt)	2023-04-25

Family

ID=63080488

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEPPCT/US2018/039878T LT3645553T (lt)	2017-06-27	2018-06-27	Modifikuoto tropizmo rekombinantinės viruso dalelės ir jų panaudojimas genetinės medžiagos tiksliniam įvedimui į žmogaus ląsteles

Country Status (30)

Country	Link
US (1)	US20200140492A1 (lt)
EP (2)	EP3645553B1 (lt)
JP (4)	JP2020525020A (lt)
KR (2)	KR20200021987A (lt)
CN (2)	CN110997699A (lt)
AU (2)	AU2018290885B2 (lt)
BR (1)	BR112019027866A2 (lt)
CA (1)	CA3066950A1 (lt)
CL (2)	CL2019003843A1 (lt)
CO (1)	CO2019014684A2 (lt)
CY (1)	CY1126149T1 (lt)
DK (1)	DK3645553T5 (lt)
ES (1)	ES2943020T3 (lt)
FI (1)	FI3645553T3 (lt)
HR (1)	HRP20230538T1 (lt)
HU (1)	HUE061908T2 (lt)
IL (2)	IL318395A (lt)
LT (1)	LT3645553T (lt)
MA (1)	MA49514B1 (lt)
MD (1)	MD3645553T2 (lt)
MX (2)	MX2020000246A (lt)
PE (2)	PE20251541A1 (lt)
PH (1)	PH12019550269B1 (lt)
PL (1)	PL3645553T3 (lt)
PT (1)	PT3645553T (lt)
RS (1)	RS64233B1 (lt)
SG (1)	SG11201911614XA (lt)
SI (1)	SI3645553T1 (lt)
SM (1)	SMT202300168T1 (lt)
WO (1)	WO2019006046A2 (lt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3151866B1 (en)	2014-06-09	2023-03-08	Voyager Therapeutics, Inc.	Chimeric capsids
AU2019227910B2 (en) *	2018-02-28	2025-07-17	The Regents Of The University Of California	A modular system for gene and protein delivery based on AAV
EP3774926A1 (en)	2018-04-05	2021-02-17	Bio-Rad ABD Serotec GmbH	Display systems for proteins of interest
GB201903479D0 (en)	2019-03-14	2019-05-01	Univ Oxford Innovation Ltd	Polypeptide with enchanced rate of spontaneous isopeptide bond formation with it's peptide tag partner and uses thereof
AU2020243460A1 (en)	2019-03-18	2021-10-07	Bio-Rad Abd Serotec Gmbh	Protection of SpyTag-containing periplasmic fusion proteins from protease Tsp and ompT degradation
KR20220011664A (ko) *	2019-05-24	2022-01-28	리제너론 파마슈티칼스 인코포레이티드	변형된 바이러스 입자 및 이의 용도
WO2020251937A1 (en) *	2019-06-11	2020-12-17	Chevron U.S.A. Inc.	Membranes for contaminant removal from natural gas and methods for use thereof
AU2020308463A1 (en) *	2019-06-26	2022-02-17	Ap Biosciences, Inc.	Antibodies for T-cell activation
GB201915905D0 (en) *	2019-11-01	2019-12-18	Spybiotech Ltd	Viruses with modified capsid proteins
EP4055034A4 (en) *	2019-11-08	2024-05-29	President And Fellows Of Harvard College	Viral capsid polypeptides
CN114634578B (zh) *	2020-12-15	2024-04-02	榕森生物科技(北京)有限公司	针对新型冠状病毒感染的疫苗组合物
CN114632148B (zh) *	2020-12-15	2024-08-09	榕森生物科技(北京)有限公司	病原样抗原疫苗及其制备方法
EP4426359A1 (en)	2021-11-04	2024-09-11	Regeneron Pharmaceuticals, Inc.	Viral particles retargeted to skeletal muscle
CN114213505B (zh) *	2021-12-10	2022-09-20	和元生物技术（上海）股份有限公司	一种适用于特异感染u87-mg细胞的腺相关病毒突变体
CA3256953A1 (en)	2022-05-09	2023-11-16	Regeneron Pharmaceuticals, Inc.	VECTORS AND METHODS FOR IN VIVO ANTIBODY PRODUCTION
EP4536836A1 (en)	2022-06-07	2025-04-16	Regeneron Pharmaceuticals, Inc.	Pseudotyped viral particles for targeting tcr-expressing cells
JP2025525792A (ja)	2022-07-29	2025-08-07	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	トランスフェリン受容体１に対して再標的化されるウイルス粒子
JP2025538220A (ja)	2022-11-14	2025-11-26	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	アストロサイトへの線維芽細胞増殖因子受容体３媒介送達のための組成物および方法
US20240168018A1 (en)	2022-11-18	2024-05-23	Regeneron Pharmaceuticals, Inc.	Methods for detecting and evaluating viruses and virus-like particles
WO2024124019A2 (en) *	2022-12-07	2024-06-13	Ginkgo Bioworks, Inc.	Aav vectors targeting hematopoietic stem cells
CN120677178A (zh)	2023-02-13	2025-09-19	瑞泽恩制药公司	用抗人cacng1抗体治疗肌肉相关病症
CN121039163A (zh)	2023-05-02	2025-11-28	瑞泽恩制药公司	抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途
TW202515999A (zh)	2023-06-20	2025-04-16	美商再生元醫藥公司	純化填充的腺相關病毒殼體之方法
WO2025018388A1 (ja) *	2023-07-20	2025-01-23	学校法人自治医科大学	抗菌カプシド、治療用組成物、殺菌剤、細菌除去方法、殺菌方法、動物治療方法、遺伝子導入方法、細菌機能追加方法、抗菌カプシドの製造方法、抗菌カプシドの標識方法、及び抗菌カプシドの細胞内送達方法
CN119552829A (zh) *	2023-09-01	2025-03-04	北京昌平实验室	靶向性基因编辑酶工程化的腺相关病毒及其药物组合物
WO2025054526A1 (en)	2023-09-07	2025-03-13	Regeneron Pharmaceuticals, Inc.	Production and purification of covalently surface modified adeno-associated virus
WO2025097030A1 (en) *	2023-11-02	2025-05-08	Oregon State University	Virus-like particles displaying neisseria gonorrhoeae antigens and use thereof for immunization against gonorrhea
WO2025111473A1 (en)	2023-11-21	2025-05-30	Regeneron Pharmaceuticals, Inc.	Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus
WO2025151796A1 (en)	2024-01-11	2025-07-17	Regeneron Pharmaceuticals, Inc.	Viral particles retargeted to nervous system tissues
WO2025155923A1 (en)	2024-01-17	2025-07-24	The Broad Institute, Inc.	Aav capsid modifications that enable improved cns-wide gene delivery through interactions with the transferrin receptor
WO2025160340A2 (en)	2024-01-26	2025-07-31	Regeneron Pharmaceuticals, Inc.	Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
CN117723749B (zh) *	2024-02-07	2024-06-04	南昌大学	基于分子粘合剂的动态光散射免疫传感检测方法
US20250277048A1 (en)	2024-03-01	2025-09-04	Regeneron Pharmaceuticals, Inc.	The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025217163A2 (en)	2024-04-08	2025-10-16	The Broad Institute, Inc.	Novel aav capsids binding to human cd59
WO2025217174A1 (en)	2024-04-08	2025-10-16	The Broad Institute, Inc.	Aav capsid modifications that enable improved cns-wide gene delivery through interactions with carbonic anhydrase iv
CN119529113A (zh) *	2024-11-28	2025-02-28	浙江大学	一种基于PCV2 VLPs的纳米抗原展示平台及制备方法和应用
CN120519522B (zh) *	2025-07-23	2025-11-18	南昌大学第一附属医院	基于双向负载模块的通用工程外泌体构建方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1286981C (zh) *	2004-11-30	2006-11-29	华中科技大学同济医学院附属同济医院	表达人类cyp2j2反义基因的重组腺相关病毒及其制备方法
ES2602610T3 (es)	2007-05-31	2017-02-21	Medigene Ag	Proteína estructural mutada de un parvovirus
MY172472A (en)	2009-12-10	2019-11-26	Regeneron Pharma	Mice that make heavy chain antibodies
GB201002362D0 (en)	2010-02-11	2010-03-31	Isis Innovation	Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
AR094403A1 (es) *	2013-01-11	2015-07-29	Hoffmann La Roche	Terapia de combinación de anticuerpos anti-her3
BR112016021572A2 (pt)	2014-03-21	2017-10-03	Regeneron Pharma	Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
US20160018835A1 (en)	2014-07-18	2016-01-21	Retroficiency, Inc.	System and method for virtual energy assessment of facilities
DE16703049T1 (de) *	2015-01-15	2018-07-12	University Of Copenhagen	Virusähnliche partikel mit effizienter epitopanzeige
CA2977434A1 (en)	2015-02-26	2016-09-01	Var2 Pharmaceuticals Aps	Immunotherapeutic targeting of placental-like chondroitin sulfate using chimeric antigen receptors (cars) and immunotherapeutic targeting of cancer using cars with split-protein binding systems
EP3141600A1 (en)	2015-09-11	2017-03-15	Institut National de la Recherche Agronomique	Nepovirus coat protein fusion polypeptides and their use
WO2018035503A1 (en)	2016-08-18	2018-02-22	The Regents Of The University Of California	Crispr-cas genome engineering via a modular aav delivery system
AU2019227910B2 (en) *	2018-02-28	2025-07-17	The Regents Of The University Of California	A modular system for gene and protein delivery based on AAV

2018
- 2018-06-27 LT LTEPPCT/US2018/039878T patent/LT3645553T/lt unknown
- 2018-06-27 HR HRP20230538TT patent/HRP20230538T1/hr unknown
- 2018-06-27 KR KR1020207001284A patent/KR20200021987A/ko not_active Ceased
- 2018-06-27 MX MX2020000246A patent/MX2020000246A/es unknown
- 2018-06-27 WO PCT/US2018/039878 patent/WO2019006046A2/en not_active Ceased
- 2018-06-27 MD MDE20200493T patent/MD3645553T2/ro unknown
- 2018-06-27 HU HUE18749636A patent/HUE061908T2/hu unknown
- 2018-06-27 CN CN201880054254.8A patent/CN110997699A/zh active Pending
- 2018-06-27 DK DK18749636.9T patent/DK3645553T5/da active
- 2018-06-27 JP JP2019572025A patent/JP2020525020A/ja active Pending
- 2018-06-27 SG SG11201911614XA patent/SG11201911614XA/en unknown
- 2018-06-27 CN CN202310837502.9A patent/CN116891534A/zh active Pending
- 2018-06-27 ES ES18749636T patent/ES2943020T3/es active Active
- 2018-06-27 PE PE2024003143A patent/PE20251541A1/es unknown
- 2018-06-27 RS RS20230411A patent/RS64233B1/sr unknown
- 2018-06-27 FI FIEP18749636.9T patent/FI3645553T3/fi active
- 2018-06-27 SM SM20230168T patent/SMT202300168T1/it unknown
- 2018-06-27 MA MA49514A patent/MA49514B1/fr unknown
- 2018-06-27 PT PT187496369T patent/PT3645553T/pt unknown
- 2018-06-27 PE PE2019002651A patent/PE20200895A1/es unknown
- 2018-06-27 KR KR1020257019410A patent/KR20250091321A/ko active Pending
- 2018-06-27 EP EP18749636.9A patent/EP3645553B1/en active Active
- 2018-06-27 BR BR112019027866-4A patent/BR112019027866A2/pt unknown
- 2018-06-27 EP EP23153644.2A patent/EP4219529A1/en active Pending
- 2018-06-27 AU AU2018290885A patent/AU2018290885B2/en active Active
- 2018-06-27 SI SI201830908T patent/SI3645553T1/sl unknown
- 2018-06-27 IL IL318395A patent/IL318395A/en unknown
- 2018-06-27 PH PH1/2019/550269A patent/PH12019550269B1/en unknown
- 2018-06-27 CA CA3066950A patent/CA3066950A1/en active Pending
- 2018-06-27 PL PL18749636.9T patent/PL3645553T3/pl unknown
- 2018-06-27 US US16/625,207 patent/US20200140492A1/en active Pending
2019
- 2019-12-19 IL IL271570A patent/IL271570A/en unknown
- 2019-12-24 CO CONC2019/0014684A patent/CO2019014684A2/es unknown
- 2019-12-26 CL CL2019003843A patent/CL2019003843A1/es unknown
2020
- 2020-01-08 MX MX2023009051A patent/MX2023009051A/es unknown
- 2020-12-30 CL CL2020003438A patent/CL2020003438A1/es unknown
2022
- 2022-10-27 JP JP2022172414A patent/JP2022186991A/ja active Pending
2023
- 2023-06-14 CY CY20231100276T patent/CY1126149T1/el unknown
- 2023-07-12 AU AU2023204611A patent/AU2023204611B2/en active Active
2024
- 2024-04-03 JP JP2024060495A patent/JP2024071769A/ja active Pending
2025
- 2025-06-26 JP JP2025108609A patent/JP2025129257A/ja active Pending

Also Published As

Publication number	Publication date
AU2018290885A1 (en)	2020-01-16
MX2023009051A (es)	2023-08-10
IL318395A (en)	2025-03-01
CL2019003843A1 (es)	2020-07-24
WO2019006046A2 (en)	2019-01-03
PL3645553T3 (pl)	2023-07-17
MA49514A (fr)	2020-05-06
RU2020101596A (ru)	2021-07-27
SMT202300168T1 (it)	2023-07-20
BR112019027866A2 (pt)	2020-07-07
HUE061908T2 (hu)	2023-09-28
PE20251541A1 (es)	2025-06-05
FI3645553T3 (fi)	2023-05-22
CN110997699A (zh)	2020-04-10
MA49514B1 (fr)	2023-06-28
DK3645553T5 (da)	2024-08-26
SG11201911614XA (en)	2020-01-30
CY1126149T1 (el)	2023-11-15
PH12019550269A1 (en)	2021-01-11
CL2020003438A1 (es)	2021-07-23
MD3645553T2 (ro)	2023-07-31
IL271570A (en)	2020-02-27
HRP20230538T1 (hr)	2023-08-04
JP2025129257A (ja)	2025-09-04
JP2020525020A (ja)	2020-08-27
CN116891534A (zh)	2023-10-17
PT3645553T (pt)	2023-05-08
CO2019014684A2 (es)	2020-01-17
PH12019550269B1 (en)	2024-05-22
ES2943020T3 (es)	2023-06-08
AU2023204611B2 (en)	2025-10-30
EP4219529A1 (en)	2023-08-02
US20200140492A1 (en)	2020-05-07
MX2020000246A (es)	2020-08-10
RS64233B1 (sr)	2023-06-30
WO2019006046A3 (en)	2019-02-14
RU2020101596A3 (lt)	2022-03-22
DK3645553T3 (da)	2023-05-22
JP2022186991A (ja)	2022-12-15
CA3066950A1 (en)	2019-01-03
EP3645553A2 (en)	2020-05-06
JP2024071769A (ja)	2024-05-24
KR20250091321A (ko)	2025-06-20
AU2018290885B2 (en)	2023-07-27
PE20200895A1 (es)	2020-09-08
SI3645553T1 (sl)	2023-06-30
KR20200021987A (ko)	2020-03-02
AU2023204611A1 (en)	2023-08-03
EP3645553B1 (en)	2023-03-15

Publication	Publication Date	Title
IL271570A (en)	2020-02-27	Recombinant viral particles that have undergone a tropism change and their uses for the targeted introduction of genetic material into human cells
IL271573A (en)	2020-02-27	Recombinant viral vectors that have undergone a tropism change and their uses for the targeted introduction of genetic material into human cells
IL266045A (en)	2019-06-30	Proteins change from secretable immunomodulators and transgenic cell therapy
IL288233A (en)	2022-01-01	Modified viral particles and their use
HUE064032T2 (hu)	2024-02-28	Pozitív elektród-anyag és alkalmazása
ZA201702632B (en)	2019-06-26	Compositions comprising recombinant bacillus cells and an insecticide
SG11202103024RA (en)	2021-04-29	Culture material and use thereof
SG11201706445SA (en)	2017-09-28	Enhanced delivery of viral particles to the striatum and cortex
PL3471177T3 (pl)	2021-10-04	Materiał czynny elektrody ujemnej i zawierająca go elektroda ujemna
IL275550A (en)	2020-08-31	Recombinant virus on a region reduced from optimal for a codon pair and its use for cancer treatment
IL290297A (en)	2022-04-01	Different cytotoxic t cells and methods of using them
SG11202110541QA (en)	2021-10-28	Multi-respiratory virus antigen-specific t cells and methods of making and using the same therapeutically
ZA202000595B (en)	2021-04-28	Novel therapeutic enzyme fusion protein and use thereof
PL3422445T3 (pl)	2021-07-19	Materiał czynny elektrody ujemnej zawierający płatki krzemu i sposób wytwarzania płatków krzemu
GB201901166D0 (en)	2019-03-20	Genetic construct and uses thereof
GB2573931B (en)	2022-01-26	Electrode material and application thereof
ZA201904386B (en)	2023-01-25	S-arrestin peptides and therapeutic uses thereof
PT3526244T (pt)	2023-12-11	Péptidos derivados do propéptido ntsr3 e a sua utilização no tratamento da depressão
HK40072139A (en)	2022-11-18	Modified viral particles and uses thereof
HK40005456A (en)	2020-05-08	Secretable variant immunomodulatory proteins and engineered cell therapy
HK1259053A1 (zh)	2019-11-22	改性硅粒子电极和方法
HK40007738A (en)	2020-06-05	Particles for delivery of proteins and peptides
GB201417148D0 (en)	2014-11-12	Eukaryotic expression vector encoding canine interleukin 12 for cancer gene therapy and the use thereof